Post on 10-Aug-2019
Normalcell Cancercell
Cancer cells have an alteredactin cytoskeleton
Oncology Research Unit, Dept Pharmacology, Level 5 Wallace Wurth
Developing novelchemotherapeutics that target
the actin cytoskeleton•• Drug DevelopmentDrug Development
– Identification of actinspecific target in tumourcells
– Determine the mechanismof action (MOA) of anti-actin compounds :
• Impact on actincytoskeleton
• Cell growth/survival– Determine if this translates
to efficacy against tumourcells anti-actin compoundsare efficacious in tumourcell lines
•• Target ValidationTarget Validation– Changes in the actin
cytoskeleton of cancer cells– Role of the actin
cytoskeleton in cancer cells• Cell growth• Cell survival
– Evaluate what happens totumour cells if specificcomponents of the actincytoskeleton are altered
• siRNA• Knockout animals
0 6 24 48hrs cAMP
G0/G1
S
G2/GM
Techniques acquired duringhonours
1) Tissue Culture 2) Immunofluorescence staining
3) Western blotting
4) Flow cytometric analysis 5) Viability assays
Projects: contact details
•• Target validation:Target validation:• Galina Schevzov (g.schevzov@unsw.edu.au)
•• Anti-actin drug developmentAnti-actin drug development• Justine Stehn (j.stehn@unsw.edu.au)